Does the media refer more to TNGX or LXRX?

In the previous week, Tango Therapeutics had 1 more articles in the media than Lexicon Pharmaceuticals. MarketBeat recorded 3 mentions for Tango Therapeutics and 2 mentions for Lexicon Pharmaceuticals. Lexicon Pharmaceuticals' average media sentiment score of 1.16 beat Tango Therapeutics' score of 0.70 indicating that Lexicon Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tango Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lexicon Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to AMLX or LXRX?

In the previous week, Amylyx Pharmaceuticals had 4 more articles in the media than Lexicon Pharmaceuticals. MarketBeat recorded 6 mentions for Amylyx Pharmaceuticals and 2 mentions for Lexicon Pharmaceuticals. Amylyx Pharmaceuticals' average media sentiment score of 1.39 beat Lexicon Pharmaceuticals' score of 1.16 indicating that Amylyx Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Amylyx Pharmaceuticals 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lexicon Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor LXRX or LEGN?

In the previous week, Legend Biotech had 4 more articles in the media than Lexicon Pharmaceuticals. MarketBeat recorded 6 mentions for Legend Biotech and 2 mentions for Lexicon Pharmaceuticals. Lexicon Pharmaceuticals' average media sentiment score of 1.16 beat Legend Biotech's score of 0.53 indicating that Lexicon Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lexicon Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Legend Biotech 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer LXRX or DNLI?

In the previous week, Denali Therapeutics had 5 more articles in the media than Lexicon Pharmaceuticals. MarketBeat recorded 7 mentions for Denali Therapeutics and 2 mentions for Lexicon Pharmaceuticals. Lexicon Pharmaceuticals' average media sentiment score of 1.16 beat Denali Therapeutics' score of 1.07 indicating that Lexicon Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lexicon Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Denali Therapeutics 5 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings & valuation, TLX or LXRX?

Telix Pharmaceuticals has higher revenue and earnings than Lexicon Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Telix Pharmaceuticals $803.79M 5.22 -$7.12M N/A N/A Lexicon Pharmaceuticals $49.80M 19.21 -$50.34M -$0.15 N/A

Does the media favor TLX or LXRX?

In the previous week, Telix Pharmaceuticals had 6 more articles in the media than Lexicon Pharmaceuticals. MarketBeat recorded 8 mentions for Telix Pharmaceuticals and 2 mentions for Lexicon Pharmaceuticals. Lexicon Pharmaceuticals' average media sentiment score of 1.16 beat Telix Pharmaceuticals' score of 0.21 indicating that Lexicon Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Telix Pharmaceuticals 0 Very Positive mention(s) 3 Positive mention(s) 2 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral Lexicon Pharmaceuticals 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Lexicon Pharmaceuticals (LXRX) Competitors

$2.15 -0.08 (-3.59%)

Closing price 09/9/2026 04:00 PM Eastern

Extended Trading

$2.19 +0.04 (+2.09%)

As of 09/9/2026 07:30 PM Eastern

Compare

LXRX vs. TNGX, AMLX, LEGN, DNLI, and TLX

Should you buy Lexicon Pharmaceuticals stock or one of its competitors? Lexicon Pharmaceuticals's main competitors and comparable companies include Tango Therapeutics (TNGX), Amylyx Pharmaceuticals (AMLX), Legend Biotech (LEGN), Denali Therapeutics (DNLI), and Telix Pharmaceuticals (TLX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Lexicon Pharmaceuticals compare to Tango Therapeutics?

Tango Therapeutics (NASDAQ:TNGX) and Lexicon Pharmaceuticals (NASDAQ:LXRX) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, earnings, valuation, dividends, institutional ownership and risk.

Tango Therapeutics has a net margin of 0.00% compared to Lexicon Pharmaceuticals' net margin of -147.38%. Tango Therapeutics' return on equity of -25.75% beat Lexicon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tango Therapeutics	N/A	-25.75%	-23.36%
Lexicon Pharmaceuticals	-147.38%	-37.53%	-24.96%

79.0% of Tango Therapeutics shares are held by institutional investors. Comparatively, 74.7% of Lexicon Pharmaceuticals shares are held by institutional investors. 6.5% of Tango Therapeutics shares are held by insiders. Comparatively, 14.0% of Lexicon Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Tango Therapeutics currently has a consensus target price of $43.46, indicating a potential upside of 81.09%. Lexicon Pharmaceuticals has a consensus target price of $4.55, indicating a potential upside of 111.63%. Given Lexicon Pharmaceuticals' higher probable upside, analysts plainly believe Lexicon Pharmaceuticals is more favorable than Tango Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tango Therapeutics	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75
Lexicon Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, Tango Therapeutics had 1 more articles in the media than Lexicon Pharmaceuticals. MarketBeat recorded 3 mentions for Tango Therapeutics and 2 mentions for Lexicon Pharmaceuticals. Lexicon Pharmaceuticals' average media sentiment score of 1.16 beat Tango Therapeutics' score of 0.70 indicating that Lexicon Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tango Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lexicon Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Lexicon Pharmaceuticals has lower revenue, but higher earnings than Tango Therapeutics. Tango Therapeutics is trading at a lower price-to-earnings ratio than Lexicon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tango Therapeutics	$62.38M	64.87	-$101.59M	-$0.85	N/A
Lexicon Pharmaceuticals	$49.80M	19.21	-$50.34M	-$0.15	N/A

Tango Therapeutics has a beta of 1.12, suggesting that its share price is 12% more volatile than the broader market. Comparatively, Lexicon Pharmaceuticals has a beta of 1.02, suggesting that its share price is 2% more volatile than the broader market.

Summary

Tango Therapeutics beats Lexicon Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

How does Lexicon Pharmaceuticals compare to Amylyx Pharmaceuticals?

Amylyx Pharmaceuticals (NASDAQ:AMLX) and Lexicon Pharmaceuticals (NASDAQ:LXRX) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, valuation, institutional ownership, analyst recommendations, earnings and risk.

In the previous week, Amylyx Pharmaceuticals had 4 more articles in the media than Lexicon Pharmaceuticals. MarketBeat recorded 6 mentions for Amylyx Pharmaceuticals and 2 mentions for Lexicon Pharmaceuticals. Amylyx Pharmaceuticals' average media sentiment score of 1.39 beat Lexicon Pharmaceuticals' score of 1.16 indicating that Amylyx Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Amylyx Pharmaceuticals	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lexicon Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

95.8% of Amylyx Pharmaceuticals shares are owned by institutional investors. Comparatively, 74.7% of Lexicon Pharmaceuticals shares are owned by institutional investors. 10.9% of Amylyx Pharmaceuticals shares are owned by company insiders. Comparatively, 14.0% of Lexicon Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Amylyx Pharmaceuticals has a net margin of 0.00% compared to Lexicon Pharmaceuticals' net margin of -147.38%. Lexicon Pharmaceuticals' return on equity of -37.53% beat Amylyx Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Amylyx Pharmaceuticals	N/A	-52.92%	-48.53%
Lexicon Pharmaceuticals	-147.38%	-37.53%	-24.96%

Amylyx Pharmaceuticals currently has a consensus price target of $36.50, indicating a potential upside of 12.65%. Lexicon Pharmaceuticals has a consensus price target of $4.55, indicating a potential upside of 111.63%. Given Lexicon Pharmaceuticals' higher possible upside, analysts clearly believe Lexicon Pharmaceuticals is more favorable than Amylyx Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amylyx Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	2 Strong Buy rating(s)	3.00
Lexicon Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Lexicon Pharmaceuticals has lower revenue, but higher earnings than Amylyx Pharmaceuticals. Amylyx Pharmaceuticals is trading at a lower price-to-earnings ratio than Lexicon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amylyx Pharmaceuticals	$87.37M	41.32	-$144.74M	-$1.43	N/A
Lexicon Pharmaceuticals	$49.80M	19.21	-$50.34M	-$0.15	N/A

Amylyx Pharmaceuticals has a beta of -0.13, meaning that its stock price is 113% less volatile than the broader market. Comparatively, Lexicon Pharmaceuticals has a beta of 1.02, meaning that its stock price is 2% more volatile than the broader market.

Summary

Amylyx Pharmaceuticals beats Lexicon Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

How does Lexicon Pharmaceuticals compare to Legend Biotech?

Lexicon Pharmaceuticals (NASDAQ:LXRX) and Legend Biotech (NASDAQ:LEGN) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, earnings, risk, institutional ownership, profitability and dividends.

Lexicon Pharmaceuticals currently has a consensus target price of $4.55, indicating a potential upside of 111.63%. Legend Biotech has a consensus target price of $53.43, indicating a potential upside of 168.35%. Given Legend Biotech's stronger consensus rating and higher probable upside, analysts plainly believe Legend Biotech is more favorable than Lexicon Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lexicon Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Legend Biotech	1 Sell rating(s)	6 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.47

Legend Biotech has a net margin of -7.21% compared to Lexicon Pharmaceuticals' net margin of -147.38%. Legend Biotech's return on equity of -8.71% beat Lexicon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lexicon Pharmaceuticals	-147.38%	-37.53%	-24.96%
Legend Biotech	-7.21%	-8.71%	-5.40%

74.7% of Lexicon Pharmaceuticals shares are held by institutional investors. Comparatively, 70.9% of Legend Biotech shares are held by institutional investors. 14.0% of Lexicon Pharmaceuticals shares are held by company insiders. Comparatively, 0.0% of Legend Biotech shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Lexicon Pharmaceuticals has higher earnings, but lower revenue than Legend Biotech. Legend Biotech is trading at a lower price-to-earnings ratio than Lexicon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lexicon Pharmaceuticals	$49.80M	19.21	-$50.34M	-$0.15	N/A
Legend Biotech	$1.03B	3.75	-$296.80M	-$0.25	N/A

In the previous week, Legend Biotech had 4 more articles in the media than Lexicon Pharmaceuticals. MarketBeat recorded 6 mentions for Legend Biotech and 2 mentions for Lexicon Pharmaceuticals. Lexicon Pharmaceuticals' average media sentiment score of 1.16 beat Legend Biotech's score of 0.53 indicating that Lexicon Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lexicon Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Legend Biotech	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Lexicon Pharmaceuticals has a beta of 1.02, meaning that its share price is 2% more volatile than the broader market. Comparatively, Legend Biotech has a beta of 0.4, meaning that its share price is 60% less volatile than the broader market.

Summary

Lexicon Pharmaceuticals and Legend Biotech tied by winning 8 of the 16 factors compared between the two stocks.

How does Lexicon Pharmaceuticals compare to Denali Therapeutics?

Lexicon Pharmaceuticals (NASDAQ:LXRX) and Denali Therapeutics (NASDAQ:DNLI) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, dividends, earnings, profitability, risk and valuation.

Lexicon Pharmaceuticals has higher earnings, but lower revenue than Denali Therapeutics. Lexicon Pharmaceuticals is trading at a lower price-to-earnings ratio than Denali Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lexicon Pharmaceuticals	$49.80M	19.21	-$50.34M	-$0.15	N/A
Denali Therapeutics	$330.53M	10.43	-$512.54M	-$2.84	N/A

In the previous week, Denali Therapeutics had 5 more articles in the media than Lexicon Pharmaceuticals. MarketBeat recorded 7 mentions for Denali Therapeutics and 2 mentions for Lexicon Pharmaceuticals. Lexicon Pharmaceuticals' average media sentiment score of 1.16 beat Denali Therapeutics' score of 1.07 indicating that Lexicon Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lexicon Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Denali Therapeutics	5 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Lexicon Pharmaceuticals currently has a consensus price target of $4.55, suggesting a potential upside of 111.63%. Denali Therapeutics has a consensus price target of $35.85, suggesting a potential upside of 66.19%. Given Lexicon Pharmaceuticals' higher probable upside, equities research analysts plainly believe Lexicon Pharmaceuticals is more favorable than Denali Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lexicon Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Denali Therapeutics	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75

Lexicon Pharmaceuticals has a beta of 1.02, suggesting that its share price is 2% more volatile than the broader market. Comparatively, Denali Therapeutics has a beta of 1.01, suggesting that its share price is 1% more volatile than the broader market.

Denali Therapeutics has a net margin of 0.00% compared to Lexicon Pharmaceuticals' net margin of -147.38%. Lexicon Pharmaceuticals' return on equity of -37.53% beat Denali Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lexicon Pharmaceuticals	-147.38%	-37.53%	-24.96%
Denali Therapeutics	N/A	-55.27%	-44.24%

74.7% of Lexicon Pharmaceuticals shares are held by institutional investors. Comparatively, 92.9% of Denali Therapeutics shares are held by institutional investors. 14.0% of Lexicon Pharmaceuticals shares are held by insiders. Comparatively, 9.7% of Denali Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Lexicon Pharmaceuticals beats Denali Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Lexicon Pharmaceuticals compare to Telix Pharmaceuticals?

Telix Pharmaceuticals (NASDAQ:TLX) and Lexicon Pharmaceuticals (NASDAQ:LXRX) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, earnings, institutional ownership, profitability, valuation, analyst recommendations, risk and dividends.

Telix Pharmaceuticals presently has a consensus target price of $20.40, suggesting a potential upside of 65.32%. Lexicon Pharmaceuticals has a consensus target price of $4.55, suggesting a potential upside of 111.63%. Given Lexicon Pharmaceuticals' higher possible upside, analysts clearly believe Lexicon Pharmaceuticals is more favorable than Telix Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Telix Pharmaceuticals	0 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.86
Lexicon Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Telix Pharmaceuticals has a beta of -0.17, indicating that its stock price is 117% less volatile than the broader market. Comparatively, Lexicon Pharmaceuticals has a beta of 1.02, indicating that its stock price is 2% more volatile than the broader market.

Telix Pharmaceuticals has a net margin of 0.00% compared to Lexicon Pharmaceuticals' net margin of -147.38%. Telix Pharmaceuticals' return on equity of 0.00% beat Lexicon Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Telix Pharmaceuticals	N/A	N/A	N/A
Lexicon Pharmaceuticals	-147.38%	-37.53%	-24.96%

74.7% of Lexicon Pharmaceuticals shares are held by institutional investors. 14.0% of Lexicon Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Telix Pharmaceuticals had 6 more articles in the media than Lexicon Pharmaceuticals. MarketBeat recorded 8 mentions for Telix Pharmaceuticals and 2 mentions for Lexicon Pharmaceuticals. Lexicon Pharmaceuticals' average media sentiment score of 1.16 beat Telix Pharmaceuticals' score of 0.21 indicating that Lexicon Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Telix Pharmaceuticals	0 Very Positive mention(s)	3 Positive mention(s)	2 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral
Lexicon Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Telix Pharmaceuticals has higher revenue and earnings than Lexicon Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Telix Pharmaceuticals	$803.79M	5.22	-$7.12M	N/A	N/A
Lexicon Pharmaceuticals	$49.80M	19.21	-$50.34M	-$0.15	N/A

Summary

Telix Pharmaceuticals beats Lexicon Pharmaceuticals on 9 of the 15 factors compared between the two stocks.

Get Lexicon Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LXRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LXRX vs. The Competition

Export

Metric	Lexicon Pharmaceuticals	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$992.25M	$3.90B	$7.22B	$12.88B
Dividend Yield	N/A	3.62%	2.55%	9.95%
P/E Ratio	-14.33	12.94	271.79	25.29
Price / Sales	19.21	1,459.61	709.75	113.08
Price / Cash	N/A	107.40	77.55	52.32
Price / Book	7.17	15.81	10.63	6.26
Net Income	-$50.34M	-$22.81M	$3.48B	$357.86M
7 Day Performance	-4.87%	-0.13%	-1.19%	-0.56%
1 Month Performance	-10.42%	4.54%	1.99%	-1.04%
1 Year Performance	99.07%	46.20%	21.89%	11.31%

Lexicon Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LXRX Lexicon Pharmaceuticals	1.921 of 5 stars	$2.15 -3.6%	$4.55 +111.6%	+90.3%	$992.25M	$49.80M	N/A	140	Gap Up
TNGX Tango Therapeutics	2.6735 of 5 stars	$22.84 -2.1%	$43.46 +90.3%	+251.9%	$3.94B	$62.38M	N/A	90
AMLX Amylyx Pharmaceuticals	2.8147 of 5 stars	$33.75 -2.8%	$36.50 +8.1%	+208.3%	$3.87B	$87.37M	N/A	200	Positive News
LEGN Legend Biotech	3.0973 of 5 stars	$20.78 +4.5%	$52.29 +151.6%	-41.9%	$3.85B	$1.03B	N/A	2,965
DNLI Denali Therapeutics	3.2053 of 5 stars	$23.76 -1.0%	$35.85 +50.9%	+40.4%	$3.84B	$330.53M	N/A	430	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LXRX) was last updated on 9/10/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Lexicon Pharmaceuticals (LXRX) Competitors

LXRX vs. TNGX, AMLX, LEGN, DNLI, and TLX

How does Lexicon Pharmaceuticals compare to Tango Therapeutics?

Summary

How does Lexicon Pharmaceuticals compare to Amylyx Pharmaceuticals?

Summary

How does Lexicon Pharmaceuticals compare to Legend Biotech?

Summary

How does Lexicon Pharmaceuticals compare to Denali Therapeutics?

Summary

How does Lexicon Pharmaceuticals compare to Telix Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LXRX vs. The Competition

Lexicon Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Lexicon Pharmaceuticals (LXRX) Competitors

LXRX vs. TNGX, AMLX, LEGN, DNLI, and TLX

How does Lexicon Pharmaceuticals compare to Tango Therapeutics?

Is TNGX or LXRX more profitable?

Do institutionals and insiders believe in TNGX or LXRX?

Do analysts recommend TNGX or LXRX?

Does the media refer more to TNGX or LXRX?

Which has stronger earnings & valuation, TNGX or LXRX?

Which has more risk and volatility, TNGX or LXRX?

Summary

How does Lexicon Pharmaceuticals compare to Amylyx Pharmaceuticals?

Does the media refer more to AMLX or LXRX?

Do insiders & institutionals have more ownership in AMLX or LXRX?

Is AMLX or LXRX more profitable?

Do analysts prefer AMLX or LXRX?

Which has better earnings & valuation, AMLX or LXRX?

Which has more volatility & risk, AMLX or LXRX?

Summary

How does Lexicon Pharmaceuticals compare to Legend Biotech?

Do analysts recommend LXRX or LEGN?

Is LXRX or LEGN more profitable?

Do insiders and institutionals have more ownership in LXRX or LEGN?

Which has better earnings & valuation, LXRX or LEGN?

Does the media favor LXRX or LEGN?

Which has more volatility and risk, LXRX or LEGN?

Summary

How does Lexicon Pharmaceuticals compare to Denali Therapeutics?

Which has better earnings & valuation, LXRX or DNLI?

Does the media prefer LXRX or DNLI?

Do analysts recommend LXRX or DNLI?

Which has more volatility & risk, LXRX or DNLI?

Is LXRX or DNLI more profitable?

Do insiders & institutionals believe in LXRX or DNLI?

Summary

How does Lexicon Pharmaceuticals compare to Telix Pharmaceuticals?

Do analysts rate TLX or LXRX?

Which has more risk and volatility, TLX or LXRX?

Is TLX or LXRX more profitable?

Do insiders & institutionals hold more shares of TLX or LXRX?

Does the media favor TLX or LXRX?

Which has stronger earnings & valuation, TLX or LXRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LXRX vs. The Competition

Lexicon Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools